Barzilai Medical Center is a 617-bed hospital in Ashkelon in southern Israel. The hospital serves a population of 500,000, including a large number of Ethiopian and Russian immigrants, and has more than 100,000 admissions annually.

During the past decade, Barzilai Medical Center conducted 99 clinical trials. In the 10-year time frame, 99 clinical trials started and 52 clinical trials were completed, i.e. on average, 52.5% percent of trials that started reached the finish line to date. In the past 5 years, 47 clinical trials started and 31 clinical trials were completed. i.e. 66% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Barzilai Medical Center" #1 sponsor was "Barzilai Medical Center" with 12 trials, followed by "Bayer" with 11 trials sponsored, "Eli Lilly and Company" with 7 trials sponsored, "Janssen Research & Development, LLC" with 7 trials sponsored and "Hoffmann-La Roche" with 7 trials sponsored. Other sponsors include 107 different institutions and companies that sponsored additional 90 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Barzilai Medical Center" #1 collaborator was "Barzilai Medical Center" with 2 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "ICON plc" with 2 trials as a collaborator, "Medgenics Medical Israel Ltd." with 2 trials as a collaborator and "Medidata Solutions" with 2 trials as a collaborator. Other collaborators include 29 different institutions and companies that were collaborators in the rest 36 trials.

According to Clinical.Site data, the most researched conditions in "Barzilai Medical Center" are "Heart Failure" (9 trials), "Rheumatoid Arthritis" (5 trials), "Chronic Kidney Disease" (4 trials), "Hereditary Angioedema" (4 trials) and "Multiple Sclerosis" (4 trials). Many other conditions were trialed in "Barzilai Medical Center" in a lesser frequency.

Most popular intervention types in "Barzilai Medical Center" are "Drug" (106 trials), "Device" (22 trials), "Other" (17 trials), "Biological" (11 trials) and "Procedure" (8 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (51 trials), "Lenalidomide" (5 trials), "Dexamethasone" (4 trials), "Bortezomib" (3 trials) and "CF101" (3 trials). Other intervention names were less common.

The vast majority of trials in "Barzilai Medical Center" are 144 trials for "All" genders and 10 trials for "Female" genders.

Currently, there are NaN active trials in "Barzilai Medical Center". undefined are not yet recruiting, 24 are recruiting, 21 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 80 completed trials in Barzilai Medical Center, 1 suspended trials, and 15 terminated clinical trials to date.

Out of the total trials that were conducted in Barzilai Medical Center, 7 "Phase 1" clinical trials were conducted, 37 "Phase 2" clinical trials and 67 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 10 trials, and there were also 23 trials that are defined as “Not Applicable".

Barzilai Medical Center has several departments that took part in Clinical trials: "Barzilai; Rheumatology" - 4 trials, "Barzilai Medical Center; Neurology Department" - 3 trials